This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Enios Applications Private Limited Company, National Institute of Health and Medical Research, Centre Eugene Marquis. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 2 
2 out of 1,853 
1 out of 2 
Years Active: 2022
Title: Aristotelis Chatziioannou: Innovator in Cancer Therapy Selection
Introduction
Aristotelis Chatziioannou is a notable inventor based in Kallithea, Greece. He has made significant contributions to the field of cancer therapy through his innovative methods and research. With a total of 2 patents, his work focuses on improving treatment selection for patients suffering from various forms of cancer.
Latest Patents
One of his latest patents is titled "Method of selection of an IRE1-inhibitor therapy for patients suffering from cancer." This invention relates to a method of treatment and therapy selection for cancer patients. The patent provides the first demonstration of a dual role of IRE1 downstream signaling in cancer. The inventors show that modulation of IRE1 signaling characteristics in GBM cells controls tumor aggressiveness. Furthermore, they present evidence supporting a novel concept where IRE-downstream signals play combined roles in cancer development. In particular, XBP1s provides pro-tumoral signals, while RIDD of mRNA and miR17 elicits anti-tumoral features. Their data, obtained from established cell lines, patient tumor samples, and primary GBM lines, depict a complex scenario where IRE1 signaling orchestrates distinct aspects of GBM biology. This invention also relates to a method for predicting whether a subject will be eligible for treatment with an IRE1 RNase inhibitor.
Another significant patent is "Method of therapy selection for patients suffering from glioblastoma." This invention focuses on the critical role of CD90 in GBM migration and invasion. The inventors demonstrated that CD90 signaling through SRC, FAK, and RhoA promotes cell migration. Importantly, high CD90 expression impacts the cell response to the SRC inhibitor dasatinib. This patent relates to a method for predicting whether a subject will be eligible for treatment with a drug selected from the group consisting of SRC inhibitor, FAK inhibitor, or RhoA inhibitor by determining the expression level of CD90 in a sample obtained from the subject.
Career Highlights
Aristotelis has worked with various organizations, including Enios Applications Private Limited Company and the National Institute of Health and Medical Research. His experience in these institutions has contributed to his expertise in cancer research and therapy development.
Collaborations
He has collaborated with notable individuals in the field, including Eric
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile